IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced it has entered into a Memorandum of Understanding (MOU) with the Chulabhorn International College of Medicine (CICM), Thammasat University, based in Bangkok, Thailand, to foster academic cooperation and mutual exchange in education and research.
The MOU Signing Ceremony was held on November 13, 2025, at SBC Medical Group Co., Ltd. (Tokyo). Representing CICM, Asst. Prof. Peerapong Kitipawong, M.D. (Dean of CICM), Assoc. Prof. Punyapats Sirithanabadeekul, M.D. (Dermatologist), and Asst. Prof. Sunatra Nitayavardhana, M.D. (Dermatologist) attended the event. From SBC Medical, participants included Yuya Yoshida (Director, CFO, COO of SBC Medical), Dr. Daisuke Nakamura (Executive Medical Director, Shonan Beauty Clinic), and Dr. Hironobu Sakanishi (Director of Technical Education and Senior Technical Instructor, Shonan Beauty Clinic).
As a leading institution in international medical education, CICM is renowned in the fields of clinical and basic medical sciences within the ASEAN region. Its mission to cultivate globally minded medical professionals who contribute to the future of society aligns closely with SBC Medical’s vision of advancing safe and innovative healthcare from Asia to the world. Under this MOU, both institutions will strengthen their collaboration through the following initiatives:
-Exchange of faculty members, researchers, and students
-Development of an anatomical dissection program (cadaver)
-Joint research projects and symposia
-Development and delivery of joint educational programs
-Exchange of academic information and educational materials
-Collaboration in dermatology, aesthetic medicine, and other designated fields
Through this partnership, SBC Medical will further strengthen its world-class capabilities in medical education and research, and as a leading company shaping the future of healthcare from Asia, contribute to the advancement of safe, evidence-based, and innovative medical practices worldwide.
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Contacts
SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Head of Public Relations E-mail: pr@sbc.or.jp
ICR LLC (In the US)
Bill Zima / Managing Partner E-mail: bill.zima@icrinc.com